Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Investors Assure Pfizer’s Ian Read: We Have Your Back

Investors have indicated they support Pfizer CEO Ian Read and his strategies despite a second failed attempt at a big tax inversion deal.

Read More »

Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares

One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.

Read More »

U.S. Treasury Drops Bomb on Tax Inversion Deals

In a surprise move, the U.S. Treasury Department released a new set of rules to make it more difficult for U.S. companies to conduct so-called tax inversions.

Read More »

Gilead Snaps Up Nimbus Apollo in $1.2 Billion Deal

Gilead Sciences struck a $1.2 billion deal to acquire Cambridge, Mass.-based Nimbus Apollo Inc. for its Acetyl-CoA Carboxylase (ACC) inhibitor program.

Read More »

Bristol-Myers Squibb to Acquire Padlock Therapeutics Inc.

 Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program Expands Bristol-Myers Squibb’s immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases   March 23, 2016 06:59 AM Eastern Daylight Time   NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the […]

Read More »

ImmunogenX Acquires the Assets of Alvine Pharmaceuticals

Newport Beach, CA — March 15, 2016 Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease   ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment of autoimmune and gastrointestinal diseases, today announced that it has completed the acquisition of the non-cash assets of Alvine Pharmaceuticals, This includes the Latiglutenase (formerly […]

Read More »

Teva offers EU concessions over Allergan generics deal – EU

Teva Pharmaceutical Industries Ltd (TEVA.TA) has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan’s (AGN.N) generics unit which will cement its position as the world’s largest generics drugmaker.   “Commitments have been submitted and the new legal deadline is set on 10 March,” European Commission spokesman Ricardo Cardoso said […]

Read More »

After a Troubling 2015, Avalanche Biotech Marries Gene Therapy Firm for a Fresh Start

Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger – Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT MENLO PARK, Calif. and PARIS, Feb. 01, 2016 (GLOBE NEWSWIRE) — Avalanche Biotechnologies, Inc. (“Avalanche”) (Nasdaq:AAVL) and Annapurna Therapeutics SAS (“Annapurna”), […]

Read More »

Drugmaker Abbott Snaps Up Alere for $5.8 Billion

ABBOTT PARK, Ill. – Waltham, Mass.-based Alere Inc. (ABT)’s stock is up more than 45 percent following news of its acquisition by Chicago-based Abbott Laboratories (ABT) this morning. Alere’s stock is trading at $54.01 per share. Up $16.81 in pre-market sales. Abbott announced this morning it was acquiring Alere Inc. for $5.8 billion in an […]

Read More »

Pershing Square’s Bill Ackman Writes Letter of Apology to Investors, Regrets Investing so Heavily into Valeant

In a 13-page letter to clients, Pershing Square Capital Management’s Bill Ackman apologized for the debacle of 2015 and, in a not-quite-a-mea-culpa, takes responsibility for some bad decisions. One of the key mistakes he takes credit for is not selling Valeant Pharmaceuticals International (VRX) stock when its share price rose over $200 in the summer. […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom